Heterogeneous Response of Airway Eosinophilia to Anti-IL-5 Biologics in Severe Asthma Patients.
airway eosinophilia
anti-IL-5 biologics
induced sputum
severe asthma
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
07 Jan 2022
07 Jan 2022
Historique:
received:
29
10
2021
revised:
04
01
2022
accepted:
05
01
2022
entrez:
21
1
2022
pubmed:
22
1
2022
medline:
22
1
2022
Statut:
epublish
Résumé
Many questions concerning responders (R) and nonresponders (NR) in severe eosinophilic asthma (SEA) after blocking the IL-5 (interleukin 5) pathway are still not clear, especially regarding the early parameters of response to biologics in personalized treatment strategies. We evaluated 17 SEA patients treated with anti-IL-5 biologics (16 patients mepolizumab, one patient benralizumab) before the introduction of biologics, and at a week 16 follow-up. Clinical, cellular and immunological parameters in peripheral blood were measured in R and NR. Sputum induction with the measurement of cellular and immunological parameters was performed at 16 weeks only. There were 12 R and 5 NR to biologics. After 16 weeks, there was a significant improvement in percentages of FEV1 (
Identifiants
pubmed: 35055384
pii: jpm12010070
doi: 10.3390/jpm12010070
pmc: PMC8781789
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Allergy Clin Immunol Pract. 2021 Mar;9(3):1194-1200
pubmed: 33069885
Chest. 2020 Aug;158(2):491-500
pubmed: 32275980
Lancet Respir Med. 2016 Jul;4(7):549-556
pubmed: 27177493
Eur Respir J. 2018 Oct 25;52(4):
pubmed: 30190274
Eur Respir J. 2020 Oct 8;56(4):
pubmed: 32444405
Am J Respir Crit Care Med. 1999 Dec;160(6):2104-17
pubmed: 10588636
J Allergy Clin Immunol Pract. 2020 Feb;8(2):736-738
pubmed: 31421278
Allergy Asthma Clin Immunol. 2017 Jan 6;13:2
pubmed: 28070196
Allergy. 2021 May;76(5):1569-1571
pubmed: 33099778
Clin Exp Allergy. 2021 Jun;51(6):811-820
pubmed: 33528864
N Engl J Med. 2009 Mar 5;360(10):973-84
pubmed: 19264686
Eur Respir J. 1996 Jun;9(6):1174-80
pubmed: 8804934
Biochem Pharmacol. 2020 Sep;179:113978
pubmed: 32305434
Am J Respir Crit Care Med. 2000 Jan;161(1):309-29
pubmed: 10619836
N Engl J Med. 2009 Mar 5;360(10):985-93
pubmed: 19264687
Eur Respir J. 2020 May 21;55(5):
pubmed: 32139455
Respirology. 2006 Jan;11(1):54-61
pubmed: 16423202
N Engl J Med. 2017 Sep 7;377(10):965-976
pubmed: 28877019
J Allergy Clin Immunol. 2019 Jul;144(1):1-12
pubmed: 31277742
N Engl J Med. 2014 Sep 25;371(13):1198-207
pubmed: 25199059
Lancet. 2006 Aug 26;368(9537):804-13
pubmed: 16935691
Qual Life Res. 2015 Mar;24(3):631-9
pubmed: 25201169
Am J Respir Crit Care Med. 2019 Feb 15;199(4):433-445
pubmed: 30525902
Eur Respir J. 2018 Dec 13;52(6):
pubmed: 30464012
Lancet. 2012 Aug 18;380(9842):651-9
pubmed: 22901886
Expert Rev Pharmacoecon Outcomes Res. 2017 Apr;17(2):121-131
pubmed: 28277854
Eur Respir J. 2014 Feb;43(2):343-73
pubmed: 24337046
Immunol Allergy Clin North Am. 2018 Nov;38(4):639-654
pubmed: 30342585
Biologics. 2017 Jun 27;11:81-95
pubmed: 28721009
Nat Rev Immunol. 2015 Jan;15(1):57-65
pubmed: 25534623
J Allergy Clin Immunol. 2015 Sep;136(3):814-6
pubmed: 25930194
J Allergy Clin Immunol. 2014 Jun;133(6):1557-63.e5
pubmed: 24332216
J Allergy Clin Immunol. 2008 Jun;121(6):1473-83, 1483.e1-4
pubmed: 18410960
J Allergy Clin Immunol. 2013 Nov;132(5):1086-1096.e5
pubmed: 23866823
Lancet Respir Med. 2018 Jan;6(1):51-64
pubmed: 28919200
Immunotherapy. 2013 Nov;5(11):1255-64
pubmed: 24188679
Clin Exp Allergy. 2016 Jun;46(6):793-802
pubmed: 26685004
Lancet Respir Med. 2015 Nov;3(11):824-5
pubmed: 26493937
Lancet. 2002 Nov 30;360(9347):1715-21
pubmed: 12480423
Am J Respir Crit Care Med. 2015 Sep 15;192(6):660-8
pubmed: 26161792
J Allergy Clin Immunol. 2015 Mar;135(3):822-4.e2
pubmed: 25445828